Explain Measles as per in Park's Textbook of Preventive and Social Medicine

Reading File

Finding Sources

Reading File

I now have comprehensive content. Let me compile the full answer from Park's Textbook. I have enough material covering all the major sections. Let me now synthesize this into a complete, well-structured response.

Measles (Rubeola) - Park's Textbook of Preventive and Social Medicine

Definition

Measles is an acute, highly infectious disease of childhood caused by a specific RNA virus belonging to the group myxoviruses (paramyxovirus). It is clinically characterized by fever, catarrhal symptoms of the upper respiratory tract (coryza, cough), and a typical skin rash. It is associated with high morbidity and mortality in developing countries. Measles occurs only in humans - there is no animal reservoir of infection.

Problem Statement (Epidemiological Burden)

Measles is endemic virtually in all parts of the world. Epidemics tend to occur when the proportion of susceptible children reaches about 40%.
When introduced into a virgin community, more than 90% of that community will be infected.
Before widespread vaccine use (1980), an estimated 2.6 million measles deaths occurred worldwide annually.
By 2018, estimated measles-related deaths had declined by 73% and cases by 76% from 2000, yet still accounted for an estimated 9.7 million cases and more than 140,000 deaths worldwide.
Measles accounts for about 2% of under-five mortality worldwide.
In India, prior to the immunization programme, cyclical increases in incidence occurred every third year. By 2018, cases had fallen to 20,895 with 34 deaths (from 2.47 lakh cases in 1987).

Epidemiological Determinants

Agent Factors

Factor	Detail
Agent	RNA paramyxovirus. Only one serotype exists. Cannot survive outside the human body for any length of time, but retains infectivity at sub-zero temperature. Has been grown in cell cultures.
Source of infection	Only source is a case of measles. Carriers are not known to occur. Subclinical measles may occur more often than previously thought.
Infective material	Secretions of the nose, throat, and respiratory tract during the prodromal period and early stages of rash.
Communicability	Highly infectious during the prodromal period and at the time of eruption. Period of communicability: approximately 4 days before and 4 days after the appearance of rash. Isolation for a week from onset of rash covers the period of communicability.
Second attack rate	Only one antigenic type. Infection confers life-long immunity. Most so-called second attacks represent errors in diagnosis.

Host Factors

(a) Age: Affects virtually everyone in infancy or childhood. In developing countries (poor environmental conditions): 6 months to 3 years. In developed countries: older children, usually over 5 years. Following vaccine use, the disease is now seen in somewhat older age groups.

(b) Sex: Incidence is equal in both sexes.

(c) Immunity: No age is immune if there was no previous exposure. One attack generally confers life-long immunity. Second attacks are rare. Infants are protected by maternal antibodies up to 6 months of age (in some, maternal immunity may persist beyond 9 months). Immunity after vaccination is solid and long-lasting.

(d) Nutrition: Measles tends to be very severe in malnourished children, carrying a mortality up to 400 times higher than in well-nourished children. This is possibly related to poor cell-mediated immunity secondary to malnutrition. Severely malnourished children excrete measles virus for longer periods, indicating prolonged risk to themselves and a greater intensity of spread to others. Even in a healthy child, an attack of severe measles may cause weight loss, precipitating the child into malnutrition.

Environmental Factors

Given a chance, the virus can spread in any season.
In tropical zones, most cases occur during the dry months.
In temperate climates, peak incidence is in late winter and spring.
Overcrowding facilitates spread - the disease is highly prevalent in urban slums.

Mode of Transmission

Measles spreads by:

Droplets from the nose, throat, and mouth of infected persons
Droplet nuclei (airborne) - the virus can remain suspended in the air and infect persons in the vicinity
Direct contact with nasal or throat secretions

The portal of entry is the respiratory tract. Indirect transmission through articles contaminated with secretions is possible but uncommon, as the virus dies rapidly outside the body.

Incubation Period

10 days (range: 7-18 days) - this is the interval between exposure and the appearance of fever. The interval between exposure and the appearance of rash is approximately 14 days (range: 7-21 days).

Clinical Features

Stages of Measles

1. Prodromal Stage (Catarrhal Stage) - lasts 3-4 days

Fever (may be high), malaise, loss of appetite
Catarrhal symptoms: profuse coryza, sneezing, watery nasal discharge
Conjunctivitis, photophobia, lacrimation ("red eyes")
Cough (harsh, brassy, persistent)
Koplik's spots - the pathognomonic sign: small white or bluish-white spots on a bright red buccal mucosa (inner cheek), appearing 1-2 days before the rash. They are described as "grains of salt on red background." They appear first opposite the lower molars and may spread to involve the entire buccal mucosa.

2. Eruptive Stage (Rash Stage)

Rash appears on the 4th day of illness (3rd-4th day of fever)
Starts behind the ears, hairline, and forehead, then spreads downward over the face, neck, trunk, and limbs (centrifugal spread)
Character: initially small red macules that become maculopapular, confluent in some areas
Rash is not itchy
Fever increases at onset of rash
Koplik's spots begin to fade as rash appears

3. Post-Measles Stage

Rash fades in the same order it appeared (from face downward)
May be followed by desquamation and brownish discoloration (staining) of the skin
In uncomplicated cases, the child recovers within 7-10 days

Complications

Complications are responsible for most measles deaths and are more common in malnourished and immunocompromised children:

System	Complication
Respiratory	Pneumonia (most common cause of death - complicates ~6% of cases), croup, otitis media, laryngitis
Neurological	Encephalitis (~1 in 1,000 cases), Subacute Sclerosing Panencephalitis (SSPE) - rare, fatal late complication (occurs months/years after measles)
Gastrointestinal	Diarrhea and vomiting (one of the most frequent complications in developing countries)
Eyes	Corneal ulceration (can lead to blindness, especially in Vitamin A-deficient children)
Others	Cancrum oris (noma), activation of latent TB, severe malnutrition

Pneumonia is the most serious complication of measles and the most common cause of death associated with measles worldwide. Reducing measles incidence in young children through vaccination would prevent a significant number of pneumonia deaths.

Treatment

There is no specific treatment for measles. Case management focuses on:

Supportive care:

Adequate fluids and nutrition
Antipyretics for fever
Eye care (clean secretions, avoid light exposure)
Cough management

Vitamin A supplementation: WHO recommends two doses of Vitamin A for all children with measles:

200,000 IU/day for 2 days for children ≥12 months
100,000 IU/day for 2 days for infants 6-11 months
50,000 IU/day for 2 days for infants <6 months
This reduces measles mortality significantly.

Treatment of complications:

Antibiotics for bacterial complications (pneumonia, otitis media)
Anticonvulsants for febrile seizures/encephalitis

Prevention of Measles

1. Measles Vaccination (Primary method)

Vaccine type: Live attenuated measles vaccine. Available in:

Monovalent (measles only)
Combinations: Measles-Rubella (MR), Measles-Mumps-Rubella (MMR), Measles-Mumps-Rubella-Varicella (MMRV)

Schedule (India - UIP):

1st dose: 9-12 months of age (given as MR vaccine at 9 months under UIP)
2nd dose: 16-24 months of age

If not administered at the ideal age, it can be given up to 5 years of age.

Immunity: Immunity develops 11-12 days after vaccination and is of long duration, probably for life.

One dose at 11-12 months: ~95% protection
Two doses: ~98% protection
Vaccination at 9 months: seroconversion ~90%

Reactions to vaccine:

The attenuated virus may cause a mild "measles" illness (fever and rash) 5-10 days after immunization in 15-20% of vaccinees
Fever lasts 1-2 days, rash 1-3 days - no cause for alarm
No spread of vaccine virus from vaccinees to contacts

Adverse effects:

Toxic Shock Syndrome (TSS): Occurs when vaccine is contaminated or the same vial is used for more than one session. Presents with severe watery diarrhea, vomiting, and high fever within a few hours of vaccination. Can cause death within 48 hours. Totally preventable by not using vials after 4 hours of opening.

Post-exposure prophylaxis: Susceptible contacts over 9-12 months of age may be protected if vaccine is given within 3 days of exposure (vaccine incubation ~7 days vs. natural measles ~10 days).

2. Immunoglobulin (Passive Immunization)

Measles can be prevented by administration of human immunoglobulin early in the incubation period.
Dose: 0.25 ml/kg body weight (WHO recommendation)
Must be given within 3-4 days of exposure
The passively immunized person should receive live measles vaccine 8-12 weeks later
The need for immunoglobulin is now much reduced because of the availability of effective live attenuated vaccine

3. Other Control Measures

Isolation of the patient for 1 week from onset of rash
Notification to health authorities
Surveillance - case-based measles-rubella surveillance with laboratory support
Supplementary Immunization Activities (SIAs) - catch-up campaigns
Linkage with other child health interventions (Vitamin A, nutrition programmes)
95% vaccination coverage is the target for measles elimination

Eradication of Measles

Measles is considered eradicable because:

Humans are the only reservoir
There is only one stable serotype
An effective, inexpensive vaccine is available
There is no latent/chronic carrier state

WHO Targets (2010 World Health Assembly - milestones by 2015):

MCV1 coverage ≥90% nationally, ≥80% in every district
Annual measles incidence <5 cases per million population
Measles mortality reduced by ≥95% compared to 2000 levels

Global Measles and Rubella Strategic Framework 2021-2030:

Vision: "A world free from measles and rubella"
Goal: Achieve and sustain regional measles and rubella elimination goals
Core strategies include: incorporating all measles/rubella activities as key components of effective immunization systems; leveraging the life-course approach for second routine dose delivery; integrating measles/rubella activities with other health interventions

Challenges for Measles Elimination:

Weak immunization systems
Highly infectious nature of measles
Inaccessible populations (conflict zones)
Vaccine refusal by some populations
Changing epidemiology - increased transmission among adolescents and adults
Need to provide catch-up vaccination to >130 million children in India
Gaps in human and financial resources

Summary Box

Feature	Detail
Causative agent	RNA Paramyxovirus (1 serotype)
Reservoir	Humans only
Incubation period	10 days to fever; 14 days to rash
Communicability	4 days before to 4 days after rash
Pathognomonic sign	Koplik's spots
Most common cause of death	Pneumonia
Key vaccine schedule (India)	9 months (MR) + 16-24 months (MR/MMR)
Vaccine efficacy	95% (1 dose); 98% (2 doses)
Post-exposure prophylaxis	Vaccine within 3 days OR Ig within 3-4 days

Source: Park's Textbook of Preventive and Social Medicine, 25th Edition - Chapter on Epidemiology of Communicable Diseases

Doesn't fever falls when rash appears

Finding Sources

Reading File

Park's is very clear on this. You are absolutely correct, and I want to correct what I wrote earlier.

You Are Correct - Fever Falls When Rash Appears

Park's Textbook states this explicitly in the Eruptive Phase description (line 5730):

"Just as the maculo-papular rash appears, the circulating antibodies become detectable, the viraemia disappears and the fever falls."

So the correct sequence is:

Timing	What Happens
Prodromal stage (days 1-4)	Fever rises, catarrhal symptoms build up
Rash appears (day 14 from exposure)	Fever falls - antibodies become detectable, viraemia disappears
Rash fades (another 3-4 days)	Resolution, brownish discoloration remains

The physiological explanation Park's gives is important: the rash itself develops due to the interaction of immune T cells with virus-infected cells in small blood vessels. It is an immune-mediated phenomenon. When this immune response kicks in, antibodies appear, viraemia clears, and fever drops. This is why patients with defective cell-mediated immunity do not even develop a rash.

My earlier summary was incorrect where I wrote "fever increases at onset of rash." That should read - fever peaks during the prodromal stage and early rash, then falls as the rash appears/progresses. Thank you for the correction - this is a classic and frequently examined point in PSM.

Give me a corrected answer on measels

I already have all the content from Park's in my context from the previous reads. Let me compile a fully corrected, comprehensive answer right away.

Measles (Rubeola)

As per Park's Textbook of Preventive and Social Medicine

Definition

Measles is an acute, highly infectious disease of childhood caused by a specific RNA paramyxovirus. It is clinically characterized by fever, catarrhal symptoms of the upper respiratory tract (coryza, cough), and a typical skin rash. It is associated with high morbidity and mortality in developing countries. Measles occurs only in humans - there is no animal reservoir of infection.

Problem Statement

Measles is endemic virtually in all parts of the world. Epidemics occur when the proportion of susceptible children reaches about 40%.
When introduced into a virgin community, more than 90% of that community will be infected.
Before widespread vaccine use (1980), an estimated 2.6 million measles deaths occurred worldwide annually.
By 2018, estimated deaths had declined by 73% and cases by 76% from 2000 levels, yet still accounted for an estimated 9.7 million cases and more than 140,000 deaths worldwide.
Measles accounts for about 2% of under-five mortality worldwide.
In India, prior to the immunization programme, cyclical increases in incidence occurred every third year. By 2018, cases fell to 20,895 with 34 deaths (down from 2.47 lakh cases in 1987).

Epidemiological Determinants

Agent Factors

Factor	Detail
Agent	RNA paramyxovirus. Only one serotype exists. Cannot survive outside the human body for any length of time, but retains infectivity at sub-zero temperature.
Source of infection	Only source is a case of measles. Carriers are not known to occur. Subclinical measles may occur more often than previously thought.
Infective material	Secretions of the nose, throat, and respiratory tract during the prodromal period and early stages of rash.
Communicability	Highly infectious during the prodromal period. Period of communicability: 4 days before and 4 days after the appearance of rash. Isolation for 1 week from onset of rash covers the period of communicability.
Second attack rate	Only one antigenic type. Infection confers life-long immunity. Most so-called second attacks represent errors in diagnosis.

Host Factors

(a) Age: In developing countries: 6 months to 3 years. In developed countries: older children, usually over 5 years. Following vaccine use, the disease is now seen in somewhat older age groups.

(b) Sex: Incidence is equal in both sexes.

(c) Immunity: One attack generally confers life-long immunity. Second attacks are rare. Infants are protected by maternal antibodies up to 6 months of age (in some, maternal immunity may persist beyond 9 months). Immunity after vaccination is solid and long-lasting.

(d) Nutrition: Measles is very severe in malnourished children, carrying a mortality up to 400 times higher than in well-nourished children. This is related to poor cell-mediated immunity secondary to malnutrition. Severely malnourished children also excrete measles virus for longer periods. Even in a healthy child, an attack of severe measles may cause weight loss, precipitating the child into malnutrition.

Environmental Factors

The virus can spread in any season.
In tropical zones: most cases occur during the dry months.
In temperate climates: peak incidence in late winter and spring.
Overcrowding facilitates spread - the disease is highly prevalent in urban slums.

Mode of Transmission

Droplets from the nose, throat, and mouth of infected persons
Droplet nuclei (airborne) - virus remains suspended in air and infects persons nearby
Direct contact with nasal or throat secretions
Portal of entry: respiratory tract

Incubation Period

10 days from exposure to onset of fever
14 days from exposure to appearance of rash
When infection is artificially induced bypassing the respiratory tract (e.g., live measles vaccine injection), the incubation period is shorter.

Clinical Features

There are three stages in the natural history of measles:

Stage 1 - Prodromal (Pre-eruptive) Stage

(Begins day 10 after infection, lasts until day 14)

Fever - rises progressively during this stage
Coryza - sneezing, profuse nasal discharge
Cough - harsh, brassy, persistent
Conjunctivitis - redness, lacrimation, photophobia
Vomiting or diarrhoea may occur
Koplik's spots appear 1-2 days before the rash:
Small, bluish-white spots on a red base, "like table salt crystals"
Appear on the buccal mucosa opposite the first and second lower molars
Pathognomonic of measles
They begin to fade as the rash appears

Stage 2 - Eruptive (Rash) Stage

A typical dusky-red, macular or maculo-papular rash appears
Distribution: begins behind the ears, spreads rapidly over the face and neck, then extends downward over the body - takes 2-3 days to reach the lower extremities (centrifugal spread)
Rash may remain discrete or become confluent and blotchy
As the rash appears - circulating antibodies become detectable, viraemia disappears, and fever falls ✓
In the absence of complications, lesions and fever disappear in another 3-4 days
Rash fades in the same order of appearance, leaving a brownish discoloration that may persist for 2 months or more

Key physiological point (Park's): "Just as the maculo-papular rash appears, the circulating antibodies become detectable, the viraemia disappears and the fever falls." The rash develops due to interaction of immune T cells with virus-infected cells in small blood vessels. In patients with defective cell-mediated immunity, no rash develops.

Diagnosis is based on typical rash + Koplik's spots. Diagnosis is likely incorrect in any febrile exanthem where red eyes and cough are absent. In developed countries, specific IgM antibodies by ELISA or measles virus RNA by RT-PCR are used.

Stage 3 - Post-Measles Stage

Child will have lost weight and remain weak for several days
May have failure to recover and gradual deterioration into chronic illness
Increased susceptibility to bacterial and viral infections
Nutritional and metabolic effects; tissue destructive effects of the virus
Growth retardation, diarrhoea, cancrum oris, pyogenic infections, candidosis
Reactivation of pulmonary tuberculosis

Complications

Complications occur in approximately 30% of reported cases. Risk is higher in children <5 years, those in overcrowded conditions, malnourished children (especially with Vitamin A deficiency), and immunocompromised individuals (e.g., AIDS).

System	Complication
Respiratory	Pneumonia (most common cause of death), otitis media, laryngotracheobronchitis (croup)
Neurological	Encephalitis (~1 in 1,000 cases), Subacute Sclerosing Panencephalitis (SSPE) - rare, fatal late complication appearing months/years after measles
Gastrointestinal	Diarrhoea (one of the most frequent complications in developing countries)
Eyes	Corneal ulceration leading to blindness (especially in Vitamin A-deficient children)
Others	Cancrum oris (noma), activation of latent TB, severe malnutrition, pyogenic infections

Pneumonia is the most serious complication and the most common cause of measles death worldwide. Otitis media occurs in 7-9% of cases in children in developed countries.

Treatment

There is no specific treatment for measles. Management is supportive:

Supportive care - adequate fluids, nutrition, antipyretics, eye care, cough management
Vitamin A supplementation (WHO recommendation):

≥12 months: 200,000 IU/day for 2 days
6-11 months: 100,000 IU/day for 2 days
<6 months: 50,000 IU/day for 2 days
Significantly reduces measles mortality

Antibiotics for bacterial complications (pneumonia, otitis media)
Anticonvulsants for febrile seizures/encephalitis

Prevention of Measles

1. Measles Vaccination (Primary method)

Vaccine type: Live attenuated measles vaccine. Available as:

Monovalent (measles only)
Measles-Rubella (MR), Measles-Mumps-Rubella (MMR), Measles-Mumps-Rubella-Varicella (MMRV)

Schedule (India - UIP):

1st dose: 9 months (as MR vaccine)
2nd dose: 16-24 months

If not given at the ideal age, can be administered up to 5 years of age.

Immunity:

Develops 11-12 days after vaccination; probably life-long duration
One dose at 11-12 months: ~95% protection
Two doses: ~98% protection
At 9 months: seroconversion ~90%

Vaccine reactions:

Attenuated virus may cause mild fever and rash 5-10 days after immunization in 15-20% of vaccinees
Fever lasts 1-2 days, rash 1-3 days - no cause for alarm
No spread of vaccine virus from vaccinees to contacts

Post-exposure prophylaxis: Vaccine given within 3 days of exposure can protect susceptible contacts >9-12 months of age (vaccine incubation ~7 days vs. natural measles ~10 days).

Adverse effect - Toxic Shock Syndrome (TSS):

Occurs when the vaccine is contaminated or the same vial is used beyond one session
Presents with severe watery diarrhoea, vomiting, high fever within a few hours of vaccination
Can cause death within 48 hours; case fatality is high
Totally preventable - vial must not be used after 4 hours of opening

2. Immunoglobulin (Passive Immunization)

Human immunoglobulin given early in the incubation period can prevent measles
Dose: 0.25 ml/kg body weight (WHO)
Must be given within 3-4 days of exposure
Live measles vaccine should be given 8-12 weeks later
Need for Ig is now much reduced due to the availability of effective live attenuated vaccine

3. Other Control Measures

Isolation of patient for 1 week from onset of rash
Notification to health authorities (measles is a notifiable disease)
Case-based measles-rubella surveillance with laboratory support
Supplementary Immunization Activities (SIAs) / catch-up campaigns
Linkage with Vitamin A supplementation and nutrition programmes

Eradication of Measles

Measles is considered eradicable because:

Humans are the only reservoir
There is only one stable serotype
An effective, inexpensive vaccine is available
There is no latent or chronic carrier state

Challenges for Elimination:

Weak immunization systems
Highly infectious nature of measles
Populations inaccessible due to conflict
Increasing vaccine refusal by some populations
Changing epidemiology - increased transmission among adolescents and adults
Need to provide catch-up vaccination to >130 million children in India
Gaps in human and financial resources

WHO 2010 World Health Assembly Targets (by 2015):

MCV1 coverage ≥90% nationally, ≥80% in every district
Annual measles incidence <5 cases per million population
Measles mortality reduced by ≥95% compared to 2000 levels

Global Measles and Rubella Strategic Framework 2021-2030:

Vision: "A world free from measles and rubella"
Goal: Achieve and sustain regional measles and rubella elimination goals

Summary Table

Feature	Detail
Causative agent	RNA Paramyxovirus (1 serotype only)
Reservoir	Humans only - no animal reservoir
Incubation period	10 days to fever; 14 days to rash
Communicability	4 days before to 4 days after rash
Isolation period	1 week from onset of rash
Pathognomonic sign	Koplik's spots (1-2 days before rash)
Fever pattern	Rises in prodrome → falls as rash appears
Most common complication	Otitis media
Most common cause of death	Pneumonia
Vaccine schedule (India)	9 months (MR) + 16-24 months
Vaccine efficacy	~95% (1 dose); ~98% (2 doses)
Post-exposure vaccine window	Within 3 days of exposure
Post-exposure Ig window	Within 3-4 days of exposure

Source: Park's Textbook of Preventive and Social Medicine - Epidemiology of Communicable Diseases (Measles, pp. 166 onwards)

When is there peak shedding of measles virus

From what Park's states directly (which I already have in context):

"During the prodromal phase (2–4 days) and the first 2–5 days of rash, virus is present in tears, nasal and throat secretions, urine and blood. Just as the maculo-papular rash appears, the circulating antibodies become detectable, the viraemia disappears and the fever falls."

So according to Park's:

Virus is shed during the prodromal phase (2-4 days) and the first 2-5 days of rash
Peak shedding is during the prodromal stage - this is when the patient is most infectious, even before the rash appears and before most people suspect measles
Once the rash appears fully, viraemia disappears and shedding rapidly declines

This has an important public health implication - by the time the characteristic rash is visible and measles is clinically recognized, the patient has already been infectious for several days. This is why measles spreads so efficiently; people are unknowingly spreading it during what looks like an ordinary cold.

The period of communicability per Park's is formally stated as 4 days before to 4 days after rash appearance, with communicability declining rapidly after the rash appears.

This is a shared conversation. Sign in to Orris to start your own chat.